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ABSTRACT
A number of factors influence the development of tolerance,
including the nature, concentration and mode of antigen
presentation to the immune system, as well as the age of the
host.  The studies were conducted to determine whether
immunizing pregnant mice with liposome-encapsulated DNA
vaccines had an effect on the immune status of their offspring.
Two different plasmids (encoding antigens from HIV-1 and
influenza virus) were administered intravenously to pregnant
mice.  At 9.5 days post conception with cationic liposomes,
injected plasmid was present in the tissues of the fetus,
consistent with trans-placental transfer.  When the offspring of
vaccinated dams were immunized with DNA vaccine, they
mounted stronger antigen-specific immune responses than
controls and were protected against challenge by homologous
influenza virus after vaccination.  Moreover, such immune
responses were strong in the offspring of mothers injected with
DNA plasmid 9.5 days after coitus.  These results suggest that
DNA vaccinated mothers confer the antigen-specific immunity
to their progeny. Here we describe the methods in detail as they
relate to our previously published work.
INTRODUCTION
Most vaccines intended for human use are administered to
infants and children. Due to the immaturity of their immune
system, newborns exposed to foreign antigens are at risk of
developing tolerance rather than immunity (2-7).  For example,
if antigen is administered shortly after birth, forbidden clones
can emerge and induce such tolerance (2-7).  A number of
factors influence the development of tolerance, including the
nature, concentration and mode of antigen presentation to the
immune system, as well as the age of the host (8,9).  Over the
past decade, there has been considerable interest in the use of
DNA vaccines to prevent infection by pathogenic viruses,
bacteria and parasites, with phase I clinical trials being initiated
against malaria, HIV-1 and hepatitis B virus.
In the present study, we confirmed that plasmid DNA
administered to pregnant mice could reach the fetus through
the placenta.  This was true both of DNA vaccines encoding
the env gene of HIV-1 as well as those encoding the influenza
virus matrix (M) and nucleoprotein (NP) genes.  Analysis of
the immune response of offspring whose mothers were
immunized with the influenza DNA vaccine indicate that these
progenies had enhanced level of protection against the same
virus infection.
MATERIALS AND METHODS
Animals
We used 6-10-week old BALB/c female mice purchased from
Japan SLC, Inc. (Shizuoka, Japan).  All mice were allowed free
access to sterile food and water.
Viral protein expression plasmids and antibodies
A pME18S-M expression plasmid was constructed with the
pME18S expression vector into which M region cDNA from
influenza virus strain A/PR/8/34 (H1N1) had been inserted
(13).  pME18S empty vector was used as a control plasmid for
A/PR/8/34 challenge.  The expression of the proteins was
confirmed by Western blot analysis (10).  pCMV160IIIB
encoding the env gene of HIV-1 strain IIIB has been described
in detail in our previous report (11).  DNA vaccines of NP
(A/pCMV-V1NP) and HA (V1J-HA (PR8)) genes of the
A/PR/8/34 strain (14-16) were the kind gifts from Drs. J. J.
Donelly and D. Montgomery, Merck Research Lab., West
Point, PA.  To confirm that plasmid DNA was transferred
through the placenta, a lacZ expression plasmid containing a
chicken b-actin promoter was also used.
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Virus Preparation (Protocol I)
Mouse-adapted influenza A/PR/8/34 (H1N1) viruses were used
in this study. Maudin-Darby canine kidney (MDCK) cells were
cultured  with  Eagle’s  minimum  essential  medium  (MEM,
Nissui Corp. Tokyo, Japan) containing 10% FCS at 5% CO2,
37
oC.  Viruses were harvested from infected MDCK cells and
titrated according to the plaque formation method.
DNA immunization (Protocol II)
Mothers were injected intravenously (i.v.) with DNA vaccine
before or after coitus.  Preparations containing various doses of
the DNA vaccine were encapsulated into liposomes (12).
Briefly,  a  1:1  volume  of  6.01  mg/ml  3b[N-(N'N'-
dimethylaminoethane) carbamoyl] cholesterol (DC-Chol) and
5.99  mg/ml  dioleoylphosphatidylethanolamine  (DOPE)  in
chloroform was mixed with an evaporator set at 40
oC for 1 hr.
Five volumes of 20 mM HEPES buffer (pH 7.8) was added
into  the  mixture,  mixed  and  kept  at  4
oC  overnight  to
completely dissolve the pellet.  Then, the resultant solution was
sonicated with a Sonifier 250 (Branson, Danbury, CT) set at
output  control  2-3;  duty  cycle  30,  for  5  min.    The  cationic
liposomes were stocked at 4
oC and used within 2-3  months.
Prior  to  administration,  an  appropriate  amount  of  DNA  in
phosphate-buffered saline (PBS), pH 7.2, was mixed with the
liposome solution at a volume ratio of 1:1.  The pregnant mice
were i.v. administered the DNA vaccine or empty vector on
various  days  after  post  conception  (p.c.)  to  assess
immunogenicity.  Six weeks after birth, their offspring  were
injected intramuscularly (i.m.) in gastrocnemius muscles with
20-50 mg of the same expression plasmid or the empty vector.
For  the  influenza  virus  challenge  experiment  50  mg  each  of
plasmids  expressing  influenza  M  and  NP  protein  was
administered  into  pregnant  mice  by  i.v.  route.    The  same
amount  of  DNA  plasmids  was  administered  to  offspring  by
i.m. route.
X-gal staining
Mouse  fetus  was  cut  in  two  and  washed  with  PBS  once
followed by incubation at 37
oC for 30 min with X-gal staining
buffer  (5  mM  K4Fe(CN)6·3H2O,  5  mM  K3Fe(CN)6,  20  mM
MgCl2, 1 mg/ml X-gal).
FISH analysis (Protocol III)
FISH analysis was performed essentially by the method of El-
Naggar et al. (17).  A 564-bp HIV  env  region  fragment  (nt
1569-2133) was  amplified  from  pCMV160IIIB  plasmid  (10)
using  primers  (5-ATGTGTAACACCTCAGTCATTAC  and
TTATCTTTTTTCTCTCTGCACCAC-3).    The  PCR  product
was  purified  from  1.5%  agarose  gel  using  QIAquick  gel
extraction kit (Qiagen) and was labeled with digoxigenin-11-
dUTP by nick translation.  The labeled product (300-560 bp
DNA)  was  confirmed  on  2%  agarose  gel  and  used  for  a
hybridization probe.  The tissue samples were taken from mice
to  which  50  mg  of  HIV  plasmid  pCMV160IIIB  (11)  or
influenza  plasmid  V1J-HA(PR8)  (14)  with  liposomes  were
administered  and  sliced  to  prepare  histological  examination.
The samples were denatured and hybridized with digoxigenin-
labeled probes using a previously described method (17).  After
hybridization, the slides were washed and stained with an anti-
digoxigenin  rhodamine  (a  red  fluorochrome:  Boehringer
Mannheim,  Germany).    The  slides  were  counterstained  with
4,6-diamino-2-phenylindole dihydrochloride (DAPI).  Images
were made with a Nikon SA fluorescence microscope (Nikon
Corp.,  Tokyo,  Japan)  and  a  Charge  Coupled  Device  (CCD)
camera  interfaced  with  a  Cyto  Vision  (Applied  Imaging,
Sunderland, UK).
Cytokine ELIspot assay (Protocol IV)
The  cytokine  ELIspot  assay  was  performed  with  minor
modifications, as previously described (18,19). Briefly, 96-well
microplates  (MAIPS4510,  Millipore,  Bedford,  MA)  were
coated with anti-mouse IFN-g rat mAb (PharMingen), and after
adding  cells  isolated  from  the  spleen  7  days  after
immunization, plates were incubated in a 5% CO2 atmosphere
at 37°C with or without 10 mg/ml of V3 peptide.  After a 24-
hour  culture,  plates  were  washed  and  incubated  again  for  2
hours with biotinylated anti-mouse IFN-g mAb (PharMingen).
Then,  after  staining  with  alkaline  phosphatase,  the  spots  in
each well were counted using a computer assisted video image
analysis system (Zeiss Co., Germany).  By applying the proper
dilution factor the total number of cytokine-secreting cells was
calculated.
Virus challenge
Under  light  diethyl  ether  anesthesia,  the  offspring  were
simultaneously  infected  with  virus  at  day  10  after
immunization with the same plasmid DNA as that administered
to  their  mothers.    Five  lethal  doses  (LD50)  of  influenza
A/PR/8/34 (H1N1) in 30 ml of PBS were administered by the
intratracheal  route  using  a  24-gauge  stainless  steel  animal
feeding tube (Popper & Sons, New York, NY).  The mortality
rate was determined after 20 days.
Statistical analysis
Statistical  analysis  for  comparison  of  two  groups  was
conducted  using  an  unpaired  t-test  or  one-way  factorial
analysis  of  variance  (ANOVA)  for  distribution  parameters.
Significance was defined as p<0.05 in both analyses.Xin et al 93
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Fig. 1: Gene expression of lacZ in mouse fetus. A and B,
Stained tissue of a fetus cut in two, whose mother received
30 mg of lacZ plasmid with liposomes at day 9.5 postcoitus
(p.c.);  C  and  D,  stained  tissue  of  a  fetus  whose  mother
received 30 mg of empty plasmid with liposomes at day 9.5
p.c.
RESULTS
Gene transfer into fetuses
Initial  studies  examined  whether  DNA  plasmids  could  be
transmitted through the placenta of pregnant mice.  To evaluate
plasmid  uptake  and  expression  in  fetal  tissue,  a  plasmid
expressing the lacZ gene was utilized.  To increase the uptake
Fig. 2: FISH analysis.  Vertebra of a fetus whose mother
received  HIV  plasmid  pCMV160IIIB  (A)  or  influenza
plasmid V1J-HA (PR8) (B) with liposomes at day 9.5 p.c.
These samples were reacted with HIV env region fragment
labeled  with  digoxigenin-11-dUTP,  followed  by  staining
with  an  antidigoxigenin  rhodamine.    Red  fluorochrome
indicates the presence of HIV-IIIB DNA.
of  this  plasmid,  it  was  liposome-encapsulated  prior  to  i.v.
delivery  (8).    Tissues  from  newborn  mice  from  mothers
injected  with  the  lacZ  plasmid  and  liposomes  9.5  days  p.c.
showed strong expression of that gene (Fig. 1).  Of particular
interest was the intense staining in the umbilical region of the
fetuses.    Examination  by  the  FISH  method  confirmed  that
abundant  plasmid  DNA  had  been  transmitted  to  the  fetuses
(Fig. 2).  We found abundant plasmid DNA in spleen, liver,
lung, and other tissues (data not shown).
ELIspot analysis using spleen cells from immunized offspring
of  vaccinated  mothers  was  performed  (Table  1).    When
stimulated in vitro with vaccine-encoded antigen, a significant
increase  in  the  number  of  spleen  cells  secreting  IFN-g was
observed.
Table 1: ELIspot analysis of IFN-g g g g producing spleen cells
from  DNA-vaccinated  mice  whose  mothers  had  been
injected with the same vaccine during pregnancy.
Immunogen administered to IFN-g producing cells
Pregnant mothers Progenies  (Spot/10
6spleen cells)
1. pCMV160IIIB pCMV160IIIB 42.6±9.6*
2. pCMV160IIIB Non-immune 20.6±6.7
3. Empty vector pCMV160IIIB 28.2±3.5*
4. Empty vector Empty vector 16.7±6.3
5. Non-immune Non-immune 13.9±5.9
At  day  9.5  p.c.,  pregnant  BALB/c  mice  were  i.v.  injected  with  50  mg  of
pCMV160IIIB  or  empty  vector  with  liposomes.    Six  weeks  after  birth  the
offspring  were  immunized i.m.  with 50  mg  of  the  same  plasmid  or  empty
vector as received by their mothers.  After 7 days, spleen cells were collected
and cocultured with V3 peptide for 24 hours.  Data represent means±SE of 6-8
mice.  *Indicates significant difference (p<0.05) compared to the empty vector
(control).  
†Means a significant difference between the two indicated  values.
Data from two other experiments showed similar results.
Challenge test with influenza virus
To  examine  the  immunoprotective  effect  of  maternal
vaccination  with  a  DNA  vaccine  against  influenza  virus,
offspring were immunized with 50 mg of the same vaccine at 6
weeks  of  age.    Seven  days  later  they  were  challenged  with
influenza virus A/PR/8/34.  More than 70% of the offspring of
vaccinated mothers survived (Fig. 3), whereas only 20% of the
offspring of non-vaccinated mothers survived.  All of the non-
immunized offspring whose mothers received liposomes alone
or were not immunized had died.
The timing of maternal DNA vaccination on the capacity of
offspring to develop protective immunity was then examined.
Whereas <20% of normal vaccinated mice (and offspring of
mothers vaccinated 20 days prior to mating) survived
the
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Fig. 3: Protection of offspring against a lethal A/PR/8/34 influenza virus challenge.  Day 9.5 p.c. pregnant BALB/c mice
were i.v. injected with 50 mg each of pME18S-M and pCMV-V1NP with or without liposomes.  Six weeks after birth, their
offspring were immunized i.m. with a total of 50 mg of the same plasmid DNA with liposomes. In one group, offspring of
mothers that had received DNA vaccine with liposomes were not administered vaccine.  In another group, the mother and
progenies received only empty vector.  Non-immunized normal mice were used as the other control.  After 7 days, all mice
were challenged with 5xLD50 of A/PR/8/34 virus.  The percentage of survival of these mice was studied for another 15 days.
n, number of mice.
challenge,  >50%  of  the  offspring  of  immunized  mothers
survived (Table 2).
These findings indicate that immunization of mothers with a
DNA vaccine against the influenza virus improves the ability
of their offspring to develop protective immunity against viral
challenge post vaccination.
DISCUSSION
Two  independent  techniques  were  used  to  establish  that
plasmid DNA administered to pregnant mice could reach the
fetus.  One is the administration of a b-gal encoding plasmid
which  allowed  for  the  direct  identification  of  protein
expression in neonates.  Intense staining of the placenta was
consistent with transplacental migration of the plasmid.  The
other technique is the FISH method which was used to directly
detect  plasmid  DNA  in fetal  tissue  (Fig.  2).    Our  results
confirm and extend the previous finding (10) that in mice a b-
gal plasmid  can  be  transmitted  through  the  placenta  to  the
fetus.  Of particular importance, we established that such trans-
placental  transfer  influences  the  recipients’  subsequent
capacity to  mount an immune response against the plasmid-
encoded antigen.  This was manifested by improved cellular
immunity  (Table  1)  and  higher  levels  of  pathogen-specific
protection (Fig. 3 and Table 2).
These studies were also performed to test the hypothesis that
the administration of a DNA  vaccine during pregnancy  may
induce antigen-specific tolerance in the offspring, as suggested
by the clonal  selection theory of Burnet (3,4,20).  Although
pregnant mice were immunized with various doses of several
different  DNA  vaccines,  we  found  that  immunity  but  not
tolerance was elicited in the fetus (Fig. 3 and Tables 1 & 2).
Using  this  technique,  we  did  not  observe  antigen-specific
immune tolerance in progeny as reported by Mor et al. (21).
This could reflect our use of a different plasmid (Mor et al.
detected  tolerance  following  neonatal  immunization  with  a
plasmid encoding the circumsporozoite protein of malaria), or
the very limited amount of plasmid actually transferred trans-
placentally.  Indeed, Ichino et al. demonstrated that neonatal
tolerance was dose-dependent, and could be reliably inducedXin et al 95
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only when >10 mg of plasmid was injected into newborn mice
(8).  This is consistent with other reports showing that low dose
antigen can induce immune responsiveness,  while  high  dose
immunization  can  induce  tolerance  in  young  recipients
(9,22,23).  This  might be in support of Burnet’s  theory that
high levels of neonatal antigen can trigger clonal deletion (4,8).
Table 2: The importance of timing the DNA immunization
of pregnant mothers against A/PR/8/34 virus challenge.
DNA vaccination of Survival after
immunization
Pregnant mothers Progeny Survivors/total
(%)
1. DNA vaccination
20 days before coitus DNA vaccination 3/19 (15.8)
day 5.5 p.c. DNA vaccination 5/20 (25.0)
day 9.5 p.c. DNA vaccination 11/21 (52.3)*
day 14.5 p.c. DNA vaccination 12/19 (63.2)*
day 9.5 p.c. no vaccination 3/18 (16.7)*
2. Empty vector
day 9.5 p.c. DNA vaccination 2/22 (9.1)
3. Non-immune control Non-immune 1/19 (5.3)
Pregnant  BALB/c  mice  were  i.v.  injected  with  25  mg  each  of  A/pCMV-
V1NP
+pME18S-M and liposomes on day 5.5, 9.5 or 14.5 p.c.  Six weeks after
birth, all offspring were immunized i.m. with 50 mg of the same plasmid DNA
as received by their mothers.  After 7 days, these mice were challenged with
5xLD50 of A/PR/8/34 and the per cent survival was determined after another
20 days.  Data represent means±SE of 19-22 mice.  *Indicates statistically
significant  difference  (p<0.05)  between  non-immune  control  group.    Data
from another separate experiment showed similar results.
When offspring of vaccinated mothers were immunized at 6
weeks  of  age  with  the  same  DNA  vaccine,  they  displayed
significant  anamnestic  responses.    Re-immunization  was
required, however,  since  trans-placental  transport  of  plasmid
alone did not trigger strong immune responses in the newborn,
or provide adequate protection from infection (Fig. 3 and Table
2).  On the other hand, re-exposure of these mice to vaccine at
6 weeks of age elicited a strong, protective immune response
characterized by antigen-specific antibody, CTL and cytokine
responses.  The administration of DNA vaccine into amniotic
fluid induced a high level of protective immunity (24).  In the
present study, when DNA vaccine was given to mothers, Ag-
specific  acquired  immunity  was  induced  in  their  offspring.
Therefore, this method may be effective in the prevention of
pertussis, hepatitis type B and C, mumps, rubella and various
other infections occurring in infants as well as animals.
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PROTOCOL I: PREPARATION OF INFLUENZA VIRUS
1. Culture MDCK cells (ATCC, No. CCL-34) in a 10 cm
2 dish with Minimum Essential Medium (MEM) containing 10% FCS
and antibiotics in a CO2 incubator at 37
oC.
2. Aspirate medium from a confluent cell monolayer.
3. Wash cells once with PBS.
4. Remove PBS and infect cells with 1 ml of FCS-free MEM containing 10
4 pfu of influenza virus.
5. Place in a CO2 incubator at 37
oC for 1 hr, rocking the dish at 15-30 min intervals to keep cells moist.
6. After 1 hr of incubation, add 10 ml of MEM medium containing 10% BSA and antibiotics, and place in a CO2 incubator at
37
oC for 3 days.
7. Store supernatant at –80
oC until use.
Titration of influenza virus
1. Prepare a 6-well tissue culture dish with confluent MDCK cells.
2. Aspirate medium and wash cells once with PBS.
3. Remove PBS and infect cells in duplicate wells with 0.5 ml of the 10
-5, 10
-6, and 10
-7 virus dilutions in FCS-free MEM
medium.
4. Place in a CO2 incubator at 37
oC for 1 hr, rocking the dish at 15-30 min intervals to keep cells moist.
5. Before the 1 hr infection is finished, melt 2% low-melt agarose and place in a 45
oC water bath to cool.  Be sure it cools to
45
oC before using it to overlay cells. Prepare and warm to 45
oC MEM medium containing 10%BSA.
6. Mix equal volumes of 2% agarose and the MEM medium from step 5.
7. Aspirate the viral inoculum from the cells (from step 4).  Overlay each well with 2 ml agarose and allow to solidify at room
temperature (RT) or 4
oC.  Place in a CO2 incubator at 37
oC for 3 days.
8. Remove the agarose and add 0.5 ml of 0.1% crystal violet to each well.  Incubate for 5 min at RT.
9. Aspirate crystal violet and allow wells to dry.
10. Determine the titre by counting plaques within the wells and multiplying by the dilution factor.Xin et al 98
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PROTOCOL II: PREPARATION OF LIPOSOME
Materials:
· L-a-phosphatidylethanolamines dioleoyl (DOPE, Avanti Polar-Lipids, Inc.)
· 3b[N-(N' N'-dimethylaminoethane) carbamoyl] cholesterol (DC-Chol, Avanti Polar Lipids, Inc.)
Preparation of 1 ml of Liposome
1. Dissolve DC-chol in chloroform at a concentration of 60.1 mg/10ml and store at –20
oC.
2. Dissolve DOPE in chloroform at a concentration of 59.9 mg/10 ml and store at –20
oC.
3. Mix 100 ml each of DC-Chol and the DOPE stock solutions.
4. Evaporate it with evaporator with gentle mixing at 40
oC.
5. Add 1 ml of HEPES buffer (sterile, pH 7.8) and dissolve the pellet completely with vortex.
6. Hydrate at 4
oC for 12 to 72 hrs.
7. Sonicate it at output 2-3, duty cycle 30 (twice for 5 min).
8. Store at 4
oC until use.
Synthesis of liposome-DNA mixture
1. Dissolve 5-50 mg of plasmid DNA in 50 ml of PBS.
2. Mix 50 ml of the DNA solution with 50 ml of liposome and pipet several times.
3. Set the liposome-DNA mixture at RT for 15 to 30 min before administration (Do not incubate the DNA with the liposome for
more than 1 hr before administration).
4. Administer 100 ml of liposome-DNA mixture per mouse.Xin et al 99
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PROTOCOL III: FLUORESCENCE IN SITU HYBRIDIZATION (FISH)
Probe Preparation
Materials:
· Digoxigenin-11-dUTP (1 nmol/ml, Roche Diagnostics Inc., Mannheim, Germany)
· DNA polymerase I (10 U/ml, GibcoBRL)
· 10 x A4 dNTP mix (Roche Diagnostics Inc., Mannheim, Germany)
· DNA polymerase I (0.5 U/ml)/DNase I (0.4 mU/ml) mix (GibcoBRL)
Probe Labeling
1. Purify PCR product from agarose gel using QIAquick gel extraction kit (Qiagen).
2. Mix following reagents at RT:
a) 10 x A4 dNTP mix, 5 ml
b) PCR DNA, 1 mg
c) Dig-11-dUTP, 1 ml
d) DNA polymerase I, 1 ml
e) DNA polymerase I/DNase I mix, 4.5 ml
f) Make up to 50 ml with H2O
3. Incubate the mixture at 15
oC for 50 min.
4. Stop the reaction at 80
oC for 10 min.
5. Check the probe on 2% agarose gel (300-560 bp DNA was visible).
Preparation of Specimen Sections
1. Remove the tissue from the animal.
2. Put the tissue in a disposable vinyl specimen mold.
3. Immediately soak specimen mold into liquid nitrogen.
4. Cut block into 10 mm thin sections.
5. Dry slides at RT for 30 min.
6. Wash slides with PBS at RT for 5 min.
7. Incubate slides in 75 mM KCl at RT for 10 min.
8. Soak slides in methanol/acetate acid mix (3 vol:1 vol) at RT for 10 min (to fix tissue).
9. Dry slides at RT for 5 min.
10. Wash slides with PBS at RT for 5 min.
11. Incubate slides with 0.005% trypsin in PBS at 37
oC for 15 min (remove protein).
12. Wash slides with PBS twice at 4
oC for 5 min.
13. Incubate slides with 10 mg/ml of RNase in SSC (degrades endogenous RNA).
14. Wash slides with PBS twice at RT for 5 min.
15. Incubate slides in 4% PFA at RT for 5 min (fix tissue).
16. Wash slides with PBS twice at RT for 5 min.
17. Incubate slides in 0.1% NP-40/2 x SSC at 37
oC for 30 min.
18. Soak slides in 70%, 85% and 100% ethanol at RT for 2 min each (to fix tissue).
Detection with FISH method
Materials:
· RNase: Make 1 mg/ml stock in 2 x SSC. Inactivate DNase by placing in boiling water for 10 min. Freeze in aliquots
suitable for 1:10 dilution.
· 20 x SSC (pH 7.00): 3 M NaCl + 0.3 M Na citrate, pH 7; filter before use.
· Master mix (50% formamide, 2 x SSC):
a) Formamide, 5 ml
b) 20 x SSC, 1 mlXin et al 100
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c) Dextran sulfate, 1 g
d) Must heat for 1-2 hrs to dissolve. Bring to pH 7.0 with HCl.  Bring volume to 7.0 ml with ddH2O.
· Denaturing solution: 70% formamide in 2 x SSC (0.7 volume formamide + 0.1 volume 20 x SSC) pH 7.0 with HCl.
Bring to volume with ddH2O.
· Hybridization wash buffer: Prepare 50% formamide in 2 x SSC (0.5 volume formamide + 0.1 volume 20 x SSC) and
adjust pH to 7.0 with HCl.  Bring to volume with ddH2O.
· 4 x SSC/0.1% Triton X-100:  Dilute 20 x SSC 1:5, adjust pH to 7.0 and then add Triton X-100 to a final concentration of
0.1%.  Autoclave.
· Anti-Digoxigenin-Rhodamine polyclonal antibody (Roche Diagnositic Inc., Mannheim, Germany): Dilute to the final
concentration with 5% skim milk in PBS.
Day 1
1. Mix:
a) Nick product, 40 ml
b) 3 M sodium acetate, 4 ml
c) Salmon sperm DNA (10 mg/ml), 4 ml
d) 100% ethanol, 100 ml
2. Keep at –80
oC for 15 min.
3. Centrifuge at 1500 rpm for 30 min in a microcentrifuge.
4. Dry up.
5. Dissolve DNA in 20 ml of a solution containing 70% master mix and 30% ddH2O.
6. Denature probe mixture at 73
oC for 5 min.
7. Place on ice.
8. Soak treated tissue slides at 73
oC denaturation solution for 5 min.
9. Incubate tissue slides with 70% ethanol for 2 min on ice.
10. Incubate tissue slides with 85% ethanol for 2 min on ice.
11. Incubate tissue slides with 100% ethanol for 2 min at RT.
12. Dry tissue slides on 37
oC hot plate.
13. Incubate with denatured probe mixture.
14. Cover the tissue slides with cover glass and seal with paper cement.
15. Incubate tissue slides at 37
oC in a moist incubator for 1-3 days.
Day 2
1. Remove paper cement and cover glass.
2. Wash slides three times at 45
oC with 50% formamide/2 x SSC for 10 min.
3. Wash slides once at 45
oC with 2 x SSC for 10 min.
4. Wash slides once at RT with 2 x SSC for 10 min.
5. Block with 5% skim milk at RT.
6. Incubate slides with anti-Digoxigenin-Rhodamine Ab (1:200 dilution, protected from light in all of the following steps).
7. Wash slides with 4 x SSC at RT for 10 min.
8. Wash slides with 4 x SSC/0.1% Triton X-100 at RT for 10 min.
9. Wash slides with 4 x SSC at RT for 10 min.
10. Wash slides with H2O at RT for 5 min.
11. Dry slides.
12. Counter stain slides with 0.05 mg/ml of 4,6-diamidino-2-phenylindole in PBS.
13. Store slides at –4
oC until counting.Xin et al 101
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PROTOCOL IV: ELISPOT ASSAY
Materials:
· Blocking solution: RPMI 1640 containing 10% FCS
· Wash buffer: 1 x PBS containing 0.05% Tween-20
· Plate: MultiScreen-IP sterile Plate, Millipore (Cat. No. MAIPS4510)
· Anti-mouse IFN-g mAb 1 mg/ml (x 100 in PBS) (PharMingen, Cat. No. 554431)
· Biotinylated anti-mouse IFN-g mAb (x 1000 in PBS) (PharMingen)
· Alkaline phosphatase streptavidin (Vector Laboratories, Inc. CA; Cat. No. SA-5100; working solution: dilute 1 ml of
alkaline phosphatase streptavidin in 5 ml of PBS containing 0.05% Tween-20 and 5% BSA just before use)
· BCIP/NBT phosphatase substrate (Kirkegaard & Perry Laboratories, Inc., MD; Cat. No. 50-81-18)
1. Incubate 50 ml/well of 100-fold diluted anti-mouse IFN-g mAb in PBS to ELIspot IP plate at 4
oC overnight.
2. Discard the mAb and wash wells once with 200 ml/well blocking solution.
3. Incubate 200 ml/well blocking solution at RT for 2 hrs.
4. Discard the blocking solution.
5. Add 200 ml/well of 10
4, 10
5 or 10
6 splenocytes with or without antigen 10 mg/ml in RPMI1640 with 10%FCS (each sample
was stimulated in triplicate with or without antigen at each dose).
6. Place the plate in a 37
oC-incubator at 5% CO2 for 24 hrs.
7. Discard the cell suspension.
8. Wash wells twice with 200 ml of ddH2O and allow wells to soak for 3-5 min at each wash step.
9. Wash wells three times with 200 ml/well wash buffer.
10. Discard the wash buffer and incubate 100 ml/well of 1,000-fold diluted Biotinylated anti-mouse IFN-g mAb at RT for 2 hrs.
11. Wash wells three times with 200 ml/well wash buffer.
12. Discard wash buffer and incubate with 50 ml/well of diluted alkaline phosphatase streptavidin at RT for 1-2 hrs.
13. Wash the plate six times with 200 ml of ddH2O containing 0.05% Tween-20.
14. Incubate the plate with 50 ml/well of BCIP/NBT phosphatase substrate at RT for 20 min-1 hr.
15. Wash the plate three times with 200 ml of ddH2O.
16. Dry the plate and count spots with a computer-assisted video image analysis (CVIA) system.